9 news items
ADAP: Initiating Coverage of Adaptimmune, a Leading T-Cell Therapy Company
ADAP
17 Jun 24
(NASDAQ:ADAP) with a 12-month price target of $3.00, translating into sizeable upside from the stock's current price
Adaptimmune to Present Data from Planned Interim Analysis of Pivotal IGNYTE-ESO Trial with Lete-cel at ASCO; Data Continue to Support further Development of Sarcoma Franchise
ADAP
3 Jun 24
therapy targeting NY-ESO-1, in synovial sarcoma (SyS) and myxoid/round cell liposarcoma (MRCLS) at the American Society of Clinical Oncology's (ASCO) annual
Why SentinelOne Shares Are Trading Lower By 16%? Here Are Other Stocks Moving In Friday's Mid-Day Session
ACIU
ADAP
AIRJ
31 May 24
Shrader initiated coverage on AC Immune with a Buy rating and announced a price target of $8.
Larimar Therapeutics, Inc
Why Zscaler Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
ADAP
ASAN
AZ
31 May 24
target guidance.
Asana, Inc. (NYSE:ASAN) rose 10.9
Adaptimmune and Galapagos Sign Clinical Collaboration Agreement with an Option to Exclusively License Adaptimmune's TCR T-cell Therapy Candidate, uza-cel, in Head & Neck Cancer and Potential Future Solid Tumor Indications
ADAP
GLPG
30 May 24
-cell therapy (uza-cel) targeting MAGE-A4 for head & neck cancer and potential future solid tumor indications, using Galapagos' decentralized cell
y97xz j8lyolkbo0o9mk6s015qb7amh
ADAP
GLPG
30 May 24
to exclusively license Adaptimmune's next-generation TCR T-cell therapy (uza-cel) targeting MAGE-A4 for head & neck cancer and potential future solid
8t3rf0yhmct0sfownj731zo03iyll366
ADAP
30 May 24
Scotiabank analyst George Farmer initiates coverage on Adaptimmune Therapeutics (NASDAQ:ADAP) with a Sector Outperform rating and announces Price Target of $3.15.
amf568rxwq2bg8pd7uwugfyb2la3efs7tdbej8076r2uwg
ADAP
17 May 24
Mizuho analyst Graig Suvannavejh maintains Adaptimmune Therapeutics (NASDAQ:ADAP) with a Buy and lowers the price target from $9 to $3.
kz8r9yn
ADAP
BDTX
DVA
23 Apr 24
apply global capabilities and perspectives to unlock high growth healthcare opportunities, targeting Pan-European and transatlantic internationalisation
- Prev
- 1
- Next